Impact of baseline tumor burden on overall survival in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial.

Naomi KiyotaMakoto TaharaBruce RobinsonMartin SchlumbergerSteven I ShermanSophie LeboulleuxEun Kyung LeeTakuya SuzukiMin RenKazuma FushimiLori J Wirth

Published in: Cancer (2022)

Patients with a lower tumor burden receiving lenvatinib had prolonged OS compared with those with a higher tumor burden receiving lenvatinib. Baseline tumor burden may be a prognostic factor for OS in patients with RAI-R DTC treated with lenvatinib.

Keyphrases

prognostic factors
risk factors
newly diagnosed